{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Drospirenone COC Survey
    A. Use of Oral Contraceptive Pills in Polycystic Ovarian Syndrome

    Oral contraceptive pills (OCPs) have been the first‑line therapy for concurrent treatment of menstrual irregularity, acne, and hirsutism in women with polycystic ovarian syndrome (PCOS), thus playing an important role in the symptom management of the PCOS women. The Combined OCP (COC) also improve dysmenorrhea and menorrhagia, treat premenstrual syndrome, prevent menstrual migraines, treat pelvic pain related to endometriosis, and decrease the risk of endometrial and ovarian cancer. Though weight reduction, exercise, and lifestyle modification are the first line of management with beneficial effects, especially in the obese PCOS women, COC have been recommended to improve the clinical manifestations.

    Please read the full text of the article here - https://pubmed.ncbi.nlm.nih.gov/30158805/
  1. Do you agree that drospirenone-ethinylestradiol combination, used as oral contraceptive, improve hyperandrogenic parameters significantly without affecting the insulin resistance adversely in Indian women with PCOS? *

  2. Do you agree that in PCOS patients with hirsutism, progestins to be preferred are the antiandrogen progestins such as drospirenone? *

  3. Do you agree that estrogen‑containing combined oral contraceptives are effective and recommended in the treatment of inflammatory acne in females? *

  4. Do you agree that combined oral contraceptives reduce endometriosis‑associated pain, dyspareunia, and dysmenorrhea? *

  5. Do you agree that combined oral contraceptive use has little‑to‑no effect on bone mineral density in premenopausal women and may preserve bone mass in those who are perimenopausal? *

  6. Do you agree that combined oral contraceptive is effective in treating irregular cycles and menorrhagia? *

    7. B. Drospirenone and ethinylestradiol for dysmenorrhea

    Dysmenorrhea refers to painful uterine cramps that occur during menstruation, concentrated in the lower abdomen, and may be accompanied by backache or other discomforts. It can be classified into primary dysmenorrhea (painful menstruation in the absence of pelvic pathology) and secondary dysmenorrhea (painful menses due to pelvic pathology or a recognized medical condition, such as endometriosis, adenomyosis, or pelvic inflammation) based on pathophysiology. Combined oral contraceptives have been used in the treatment of dysmenorrhea since their introduction for general use in 1960. The mechanism of action of COCs is to inhibit ovulation by estrogen and progesterone, thereby inhibiting the synthesis of prostaglandin. Drospirenone and ethinylestradiol is a new generation of COC which combines progestogenic, antimineralocorticoid, and antiandrogenic effects and does not exhibit any estrogenic, androgenic, or glucocorticoid effects, providing non-contraceptive benefits.

    Please read the full text of the article here - https://www.frontiersin.org/articles/10.3389/fmed.2022.938606/full
  7. For dysmenorrhea and dysmenorrhea-related disorders, combined oral contraceptive was recommended as the first-line treatment for the relief of primary or secondary dysmenorrhea in global relevant consensus and guidelines. Do you agree? *

  8. An international multicenter study showed that only 0.7% of women discontinued drospirenone-ethinylestradiol COC due to irregular bleeding, which was lower than other combined oral contraceptives. Do you agree as per your clinical experience? *

  9. Do you agree that drospirenone-ethinylestradiol COC has a good safety profile (such as low risk in thrombus, weight gain, or water-retention), good tolerability, and a low overall risk of adverse events in patients with dysmenorrhea? *

  10. A real-world study showed a significant improvement in physiological, social, and psychological health-related quality of life in dysmenorrhea patients after a cyclic regimen of drospirenone and ethinylestradiol. Do you agree as per your clinical experience? *